Windlas Biotech Limited has announced the allotment of 28,990 equity shares under its employee stock option plans on March 13, 2026. The pharmaceutical company informed both BSE and NSE exchanges about this corporate action through an official communication from Company Secretary and Compliance Officer Ananta Narayan Panda.

Share Allotment Details

The equity shares, each with a face value of Rs.5/-, were allocated across two distinct employee stock option schemes operated by the company:

Regulatory Compliance

The allotment was conducted in accordance with the company's established employee stock option schemes and regulatory requirements. Windlas Biotech has requested both stock exchanges to take this information on record as part of standard compliance procedures.

Company Information

Windlas Biotech Limited operates with its registered office located at 40/1, Mohabewala Industrial Area, Dehradun, Uttarakhand, and maintains its corporate office in Gurgaon, Haryana. The company trades on BSE under code 543329 and on NSE under the symbol WINDLAS.

The WBL Employee Stock Option Scheme 2023 accounted for the majority of the current allotment, representing approximately 86% of the total shares allocated. This employee stock option allotment reflects the company's ongoing commitment to employee participation in equity ownership through structured compensation plans.

Windlas Biotech Limited has received a show cause notice from the Office of the Commissioner, Food Safety & Drug Administration (Uttarakhand) on February 9, 2026, resulting in the temporary suspension of codeine-containing cough syrup manufacturing. The company disclosed this development through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Action Details

The Food Safety & Drug Administration authority has specifically targeted the manufacturing of codeine-containing cough syrup products. The company has confirmed that it is in the process of submitting a detailed response to the show cause notice within the stipulated timelines as required by the regulatory authority.

Financial Impact Assessment

The suspension carries significant financial implications for the pharmaceutical company:

Operational Continuity

The company has emphasized that the impact is limited exclusively to codeine-based cough syrups. All other manufacturing operations and product lines remain unaffected and continue normal production schedules. This targeted suspension allows the company to maintain most of its operational capacity while addressing the specific regulatory concerns.

Company Response and Commitment

Windlas Biotech has reiterated its commitment to maintaining the highest quality and compliant manufacturing standards across all its facilities. The company stated it will continue strengthening its compliance framework on an ongoing basis to prevent similar regulatory issues in the future.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary and compliance officer, Ananta Narayan Panda, signed the regulatory filing on February 10, 2026.